trending Market Intelligence /marketintelligence/en/news-insights/trending/78IbMMJn8rY5pqjBd9Ek6g2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

UK's NICE recommends Celgene pancreatic cancer drug for use in NHS

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


UK's NICE recommends Celgene pancreatic cancer drug for use in NHS

The U.K.'s National Institute for Health and Care Excellence, or NICE, recommended Celgene Corp.'s pancreatic cancer drug Abraxane for routine use in the National Health Service.

Celgene agreed to a confidential price discount to make the drug more cost-effective.

Abraxane can extend the life of pancreatic cancer patients by an average of 2.4 months when added to standard chemotherapy.

The life expectancy of pancreatic cancer patients is up to six months. There are almost 10,000 new cases of pancreatic cancer each year in the U.K.